CELC Logo

Celcuity Inc. (CELC) 

NASDAQ
Market Cap
$595.45M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
483 of 776
Rank in Industry
256 of 433

Largest Insider Buys in Sector

CELC Stock Price History Chart

CELC Stock Performance

About Celcuity Inc.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with …

Insider Activity of Celcuity Inc.

Over the last 12 months, insiders at Celcuity Inc. have bought $0 and sold $401,499 worth of Celcuity Inc. stock.

On average, over the past 5 years, insiders at Celcuity Inc. have bought $850,494 and sold $152,189 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 10,000 shares for transaction amount of $103,187 was made by Furcht Leo (director) on 2023‑05‑22.

List of Insider Buy and Sell Transactions, Celcuity Inc.

2024-10-23Saledirector
350
0.0009%
$16.25$5,6880.00%
2024-08-23Saledirector
350
0.0009%
$16.95$5,933-12.22%
2024-06-21Saledirector
350
0.0011%
$15.68$5,488-0.44%
2024-04-24Saledirector
350
0.0011%
$17.06$5,971-6.43%
2024-02-21Saledirector
350
0.0014%
$14.15$4,953+13.38%
2023-12-20Saledirector
350
0.0015%
$14.37$5,030+10.49%
2023-12-15Saledirector
2,940
0.0121%
$14.57$42,847+7.53%
2023-12-14Saledirector
5,000
0.0206%
$14.75$73,752+6.92%
2023-12-13Saledirector
5,000
0.0202%
$14.50$72,500+6.92%
2023-12-12Saledirector
2,060
0.0085%
$14.61$30,089+7.73%
2023-12-08Saledirector
5,000
0.0207%
$15.00$75,000+5.50%
2023-12-07Saledirector
5,000
0.0207%
$14.85$74,250+6.22%
2023-10-25Saledirector
350
0.0016%
$10.23$3,581+52.29%
2023-08-30Saledirector
350
0.0015%
$9.28$3,248+55.93%
2023-08-23Saledirector
300
0.0013%
$9.82$2,946+45.96%
2023-06-23Saledirector
300
0.0014%
$11.79$3,537+25.91%
2023-05-23Saledirector
75
0.0003%
$11.10$833+20.73%
2023-05-22Saledirector
100
0.0005%
$10.50$1,050+24.01%
2023-05-22Purchasedirector
10,000
0.0449%
$10.32$103,187+24.01%
2023-05-19Saledirector
250
0.0011%
$9.85$2,463+25.54%

Insider Historical Profitability

16.94%
Sullivan Brian F.Chief Executive Officer
3016643
8.1464%
$16.0810+9.38%
NIGON RICHARDdirector
96032
0.2593%
$16.0870+17.9%
Furcht Leodirector
10250
0.0277%
$16.0810+24.01%
Murphy Polly A.director
5000
0.0135%
$16.0810+10.68%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Perceptive Advisors$51.03M6.732.36M+59.47%+$19.03M0.03
Morgan Stanley$50.75M6.692.35M+7.02%+$3.33M<0.01
Soleus Capital Management, L.P.$37.4M4.931.73M-20.56%-$9.68M0.16
Commodore Capital, LP$33.61M4.431.56M-11.33%-$4.29M0.13
Baker Bros Advisors LP$33.53M4.421.55M+189.92%+$21.97M0.24
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.